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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to iron and 
formation of red blood cells and haemoglobin (ID 374, 2889), oxygen 
transport (ID 255), contribution to normal energy-yielding metabolism 
(ID 255), reduction of tiredness and fatigue (ID 255, 374, 2889), 
biotransformation of xenobiotic substances (ID 258), and “activity of heart, 
liver and muscles” (ID 397) pursuant to Article 13(1) of Regulation (EC) 
No 1924/20061 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to iron and formation of red blood cells and haemoglobin, oxygen transport, contribution to 
normal energy-yielding metabolism, reduction of tiredness and fatigue, biotransformation of 
xenobiotic substances and “activity of heart, liver and muscles”. The scientific substantiation is based 
on the information provided by the Member States in the consolidated list of Article 13 health claims 
and references that EFSA has received from Member States or directly from stakeholders. 
The food constituent that is the subject of the health claims is iron. The Panel considers that iron is 
sufficiently characterised. 
Formation of red blood cells and haemoglobin 
The claimed effect is “fights against anaemia/ tiredness”. The target population is assumed to be the 
general population. The Panel assumes that the claimed effect is related to the formation of red blood 
cells and haemoglobin. 
                                                     
 
1  On request from the European Commission, Question No EFSA-Q-2008-1042, EFSA-Q-2008-1045, EFSA-Q-2008-1161, 
EFSA-Q-2008-1184, EFSA-Q-2008-3622, adopted on 09 July 2010. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3 Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on 
this scientific opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen.  
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A claim on iron and normal formation of red blood cells and haemoglobin has already been assessed 
with a favourable outcome. 
Oxygen transport 
The claimed effect is “vitamin/mineral supplementation to reduce fatigue and tiredness in situations 
of inadequate micronutrient status”. The target population is assumed to be the general population. In 
the context of the clarifications provided by Member States, the Panel assumes that the claimed effect 
is related to oxygen transport. 
A claim on iron and normal oxygen transport has already been assessed with a favourable outcome. 
Contribution to normal energy-yielding metabolism 
The claimed effect is “vitamin/mineral supplementation to reduce fatigue and tiredness in situations 
of inadequate micronutrient status”. The target population is assumed to be the general population. In 
the context of the clarifications provided by Member States, the Panel assumes that the claimed effect 
is related to energy-yielding metabolism. 
A claim on iron and normal energy-yielding metabolism has already been assessed with a favourable 
outcome. 
Reduction of tiredness and fatigue 
The claimed effects are “vitamin/mineral supplementation to reduce fatigue and tiredness in situations 
of inadequate micronutrient status” and “fights against anaemia/ tiredness”. The target population is 
assumed to be the general population. The Panel considers that reduction of tiredness and fatigue is a 
beneficial physiological effect. 
The Panel concludes that a cause and effect relationship has been established between the dietary 
intake of iron and reduction of tiredness and fatigue. 
Biotransformation of xenobiotic substances 
The claimed effect is “metabolism of foreign substances”. The target population is assumed to be the 
general population. The Panel notes that from the proposed wording it could not be established which 
xenobiotic substance or which biotransformation reaction related to the elimination of xenobiotic 
substances is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
“Activity of heart, liver and muscles” 
The claimed effect is “activity of heart, liver and muscles”. The target population is assumed to be the 
general population. “Activity of heart, liver and muscles” is not sufficiently defined and no 
clarifications have been provided by Member States.  
The Panel considers that the claimed effect is general and non-specific and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
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Conditions and possible restrictions of use 
The Panel considers that in order to bear the claim a food should be at least a source of iron as per 
Annex to Regulation (EC) No 1924/2006. Such amounts can be easily consumed as part of a balanced 
diet. The target population is the general population. 
KEY WORDS 
Iron, red blood cells, haemoglobin, oxygen transport, energy-yielding metabolism, xenobiotics, fatigue, heart, 
liver, muscles, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/20064 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out5. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claims is iron which is a well recognised nutrient 
and is measurable in foods by established methods.  
Iron occurs naturally in foodstuffs in different oxidation states. The primarily occurring oxidation 
states in biological systems are +2 (ferrous state) and +3 (ferric state).  
Iron occurs naturally in foods in two forms, haem iron which is primarily derived from haemoglobin 
and myoglobin in meat and non-haem iron from plants in the form of iron complexes (IoM, 2001). 
Different forms of iron are authorised for addition to foods (Annex II of Regulation (EC) No 
1925/20066 and Annex II of Directive 2002/46/EC7). This evaluation applies to iron naturally present 
in foods and those forms authorised for addition to foods (Annex II of the Regulation (EC) No 
1925/2006 and Annex II of Directive 2002/46/EC). 
The Panel considers that the food constituent, iron, which is the subject of the health claims, is 
sufficiently characterised.  
2. Relevance of the claimed effects to human health 
2.1. Formation of red blood cells and haemoglobin (ID 374, 2889) 
The claimed effect is “fights against anaemia/ tiredness”. The Panel assumes that the target population 
is the general population.  
The Panel assumes that the claimed effect is related to the formation of red blood cells and 
haemoglobin. 
                                                     
 
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 Briefing document for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims: 
http://www.efsa.europa.eu/en/ndameetings/docs/nda100601-ax01.pdf 
6 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38. 
7 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57. 
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A claim on iron and normal formation of red blood cells and haemoglobin has already been assessed 
with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009). 
2.2. Oxygen transport (ID 255) 
The claimed effect is “vitamin/mineral supplementation to reduce fatigue and tiredness in situations 
of inadequate micronutrient status”. The Panel assumes that the target population is the general 
population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect is related to oxygen transport. 
A claim on iron and normal oxygen transport has already been assessed with a favourable outcome 
(EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009). 
2.3. Contribution to normal energy-yielding metabolism (ID 255) 
The claimed effect is “vitamin/mineral supplementation to reduce fatigue and tiredness in situations 
of inadequate micronutrient status”. The Panel assumes that the target population is the general 
population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect is related to energy-yielding metabolism. 
A claim on iron and normal energy-yielding metabolism has already been assessed with a favourable 
outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2009). 
2.4. Reduction of tiredness and fatigue (ID 255, 374, 2889) 
The claimed effects are “vitamin/mineral supplementation to reduce fatigue and tiredness in situations 
of inadequate micronutrient status” and “fights against anaemia/ tiredness”. The Panel assumes that 
the target population is the general population. 
The Panel considers that the reduction of tiredness and fatigue is a beneficial physiological effect. 
2.5. Biotransformation of xenobiotic substances (ID 258) 
The claimed effect is “metabolism of foreign substances”. The Panel assumes that the target 
population is the general population. 
Enzymatic biotransformation reactions of xenobiotic substances after absorption involve Phase I and 
Phase II biotransformation reactions, which usually work together in a sequential manner to convert 
xenobiotics into more readily excretable metabolites (Yu, 2005; Buhler and Williams, 1988). Phase I 
biotransformation reactions include oxidation, reduction, and hydrolysis, while Phase II 
biotransformation consists essentially of conjugation reactions (Yu, 2005). Whereas 
biotransformation reactions normally result in detoxification, some chemicals may also be 
enzymatically converted to highly reactive, electrophilic metabolites which may induce cytotoxic, 
teratogenic, mutagenic or carcinogenic effects through reaction with various cellular constituents 
(Buhler and Williams, 1988).  
The Panel notes that from the proposed wording it could not be established which xenobiotic 
substance or which biotransformation reaction related to the elimination of xenobiotic substances is 
the target for the claim. 
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In the absence of such information, the Panel considers that the claimed effect is general and 
non-specific and does not refer to any specific health claim as required by Regulation (EC) No 
1924/2006. 
2.6. “Activity of heart, liver and muscles” (ID 397) 
The claimed effect is “activity of heart, liver and muscles”. The Panel assumes that the target 
population is the general population. 
“Activity of heart, liver and muscles” is not sufficiently defined and no clarifications have been 
provided by Member States. 
The Panel considers that the claimed effect is general and non-specific and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
3. Scientific substantiation of the claimed effect  
Iron is an essential trace element that has important metabolic functions, including oxygen transport, 
and is involved in many redox reactions. Insufficient intake results in the deficiency condition 
anaemia, adverse outcomes of pregnancy, impaired psychomotor development and cognitive 
performance and reduced immune function (EFSA, 2004). 
3.1. Reduction of tiredness and fatigue (ID 255, 374, 2889) 
Insufficient intake of iron results in the deficiency condition anaemia. Most patients with significant 
anaemia are fatigued and tire easily after exertion (Chitambar and Antony, 2006). 
The Panel concludes that a cause and effect relationship has been established between the dietary 
intake of iron and reduction of tiredness and fatigue. 
4. Panel’s comments on the proposed wording 
4.1. Reduction of tiredness and fatigue (ID 255, 374, 2889) 
The Panel considers that the following wording reflects the scientific evidence: “Iron can contribute 
to the reduction of tiredness and fatigue”. 
5. Conditions and possible restrictions of use  
The Panel considers that in order to bear the claims a food should be at least a source of iron as per 
Annex to Regulation (EC) No 1924/2006. Such amounts can be easily consumed as part of a balanced 
diet. The target population is the general population. No Upper Tolerable Intake Levels (UL) have 
been set for iron (EFSA, 2004). 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, iron, which is the subject of the health claims, is sufficiently 
characterised. 
Iron related health claims 
 
9 EFSA Journal 2010;8(10):1740 
Formation of red blood cells and haemoglobin (ID 374, 2889) 
 The claimed effect is “fights against anaemia/tiredness”. The target population is assumed to 
be the general population. It is assumed that the claimed effect is related to the formation of 
red blood cells and haemoglobin. 
 A claim on iron and normal formation of red blood cells and haemoglobin has already been 
assessed with a favourable outcome. 
Oxygen transport (ID 255) 
 The claimed effect is “vitamin/mineral supplementation to reduce fatigue and tiredness in 
situations of inadequate micronutrient status”. The target population is assumed to be the 
general population. In the context of the clarifications provided by Member States, it is 
assumed that the claimed effect is related to oxygen transport. 
 A claim on iron and normal oxygen transport has already been assessed with a favourable 
outcome. 
Contribution to normal energy-yielding metabolism (ID 255) 
 The claimed effect is “vitamin/mineral supplementation to reduce fatigue and tiredness in 
situations of inadequate micronutrient status”. The target population is assumed to be the 
general population. In the context of the clarifications provided by Member States, it is 
assumed that the claimed effect is related to energy-yielding metabolism. 
 A claim on iron and normal energy-yielding metabolism has already been assessed with a 
favourable outcome. 
Reduction of tiredness and fatigue (ID 255, 374, 2889) 
 The claimed effects are “vitamin/mineral supplementation to reduce fatigue and tiredness in 
situations of inadequate micronutrient status” and “fights against anaemia/tiredness”. The 
target population is assumed to be the general population. Reduction of tiredness and fatigue 
is a beneficial physiological effect. 
 A cause and effect relationship has been established between the dietary intake of iron and 
reduction of tiredness and fatigue. 
 The following wording reflects the scientific evidence: “Iron can contribute to the reduction 
of tiredness and fatigue”. 
Biotransformation of xenobiotic substances (ID 258) 
 The claimed effect is “metabolism of foreign substances”. The target population is assumed to 
be the general population. From the proposed wording, it could not be established which 
xenobiotic substance or which biotransformation reaction related to the elimination of 
xenobiotic substances is the target for the claim. 
 The claimed effect is general and non-specific and does not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. 
Iron related health claims 
 
10 EFSA Journal 2010;8(10):1740 
“Activity of heart, liver and muscles” (ID 397) 
 The claimed effect is “activity of heart, liver and muscles”. The target population is assumed 
to be the general population. “Activity of heart, liver and muscles” is not sufficiently defined 
and no clarifications have been provided by Member States.  
 The claimed effect is general and non-specific and does not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. 
Conditions and possible restrictions of use  
 In order to bear the claims a food should be at least source of iron as per Annex to Regulation 
(EC) No 1924/2006. Such amounts can be easily consumed as part of a balanced diet. The 
target population is the general population. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1042, 
EFSA-Q-2008-1045, EFSA-Q-2008-1161, EFSA-Q-2008-1184, EFSA-Q-2008-3622). The scientific 
substantiation is based on the information provided by the Members States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods8 (hereinafter "the 
Regulation") entered into force on 19th January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD9  
Foods are commonly involved in many different functions10 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
 
8 OJ  L12, 18/01/2007 
9 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
10 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
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 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate:  
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to iron, including conditions of use from similar claims, as 
proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
255 Iron 
 
Vitamin/mineral 
supplementation to reduce 
fatigue and tiredness in 
situations of inadequate 
micronutrient status 
Clarification provided 
Iron is required for optimal 
circulating levels of oxygen 
and energy use by the body 
Supplementation with B-
vitamins, iron, magnesium as 
well as vitamin C can reduce 
fatigue and tiredness in 
situations of inadequate micro-
nutrient status 
Conditions of use 
 Erwachsene: 2-15 Milligramm (mg) 14 - 30 Tage 
 Must meet minimum requirements for use of the claim "source of [name of vitamin/s] 
and/or [name of mineral/s]," as per Annex to Regulation 1924/2006. 
ID Food or Food constituent Health Relationship Proposed wording 
258 
 
Iron Metabolism of foreign 
substances 
 
Iron is needed to allow the body 
metabolise drugs and other 
substances. Iron contributes to 
the body’s ability to metabolise 
drugs and other substances. 
Iron is needed for the 
metabolism of drugs. 
Conditions of use 
 Jugendliche, Erwachsene: 3 bis 10 Milligramm (mg) 
 MUST AT LEAST BE A SOURCE OF MINERAL/S AS PER ANNEX TO 
REGULATION 1924/2006, Agency guidance for supplements is that Products containing 
>20mg Iron should carry the label statement: '[This amount of iron] may cause mild 
stomach upset in sensitive individuals.', Applicable to both children and adults 
 No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
374 
 
Fer 
Clarification provided 
iron 
lutte contre l'anémie/ la fatigue 
Clarification provided 
fights against anemia/ 
tiredness 
le fer vous aidera à lutter 
contre la fatigue 
Clarification provided 
iron will help you to fight 
against tiredness. 
 Conditions of use 
 source de (selon annexe règlement CE/1924/2006) 
Iron related health claims 
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ID Food or Food constituent Health Relationship Proposed wording 
397 Iron activity of heart, liver and 
muscles 
Iron affects activity of heart, 
liver and muscles.  
 Conditions of use 
 The product must contain at least 15 % of the RDA 
 No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2889 Fer lutte contre l'anémie/ la fatigue le fer vous aidera à lutter 
contre la fatigue 
 Conditions of use 
 source de (selon annexe règlement CE/1924/2006) 
 No clarification provided by Member States 
 
 
